A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Comparability Study To Assess The Pharmacokinetics Of Pf-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2016
At a glance
- Drugs Adalimumab (Primary)
- Indications Immunological disorders; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 03 Jun 2016 Status changed from recruiting to completed.
- 17 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 19 Jan 2016 Planned End Date changed from 1 Jul 2016 to 1 Jun 2016, according to ClinicalTrials.gov record